Lockheed Martin and Eli Lilly are reliable dividend stocks with strong track records of rewarding their shareholders with increasing cash payments. Lockheed Martin, a leading defense contractor, has a robust backlog of orders totaling $159 billion and key products expected to remain in service for decades, providing investors with a clear view of future cash flow. The company has a history of stock buybacks and consistent dividend increases over the past 21 years, offering shareholders a solid dividend yield of 2.7%. On the other hand, Eli Lilly, with a history of medical breakthroughs, has developed a game-changing drug called Zepbound for weight management, which has shown promising results in clinical trials. With the drug's potential to tap into a growing anti-obesity market projected to reach $130 billion by 2030, Eli Lilly's profits are expected to surge by over 60% annually in the next five years.